Merck KGaA Acquires PostEra's Oral Fertility Drug Programs
- Merck KGaA, through its EMD Serono fertility business, has agreed to acquire two oral small-molecule fertility drug candidate programs from PostEra for an undisclosed sum described as "mid-double-digit millions."
- Both programs are orally administered small molecules, contrasting with the injectable biologics that currently dominate fertility treatment.
- One program comprises FSHR (Follicle-Stimulating Hormone Receptor) agonists intended for ovarian stimulation during IVF.
- The other comprises LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor) agonists aimed at male infertility and triggering ovulation during IVF.
- PostEra, an AI-driven drug-design startup named one of C&EN's "10 Start-Ups to Watch" in 2025, developed both candidate series using its computational platform.
A bolt-on, not a market entry: EMD Serono is already a top-three fertility player commercially, so this reinforces an existing franchise rather than opening a new front — low-risk portfolio strategy. The real story is oral-vs-injectable: IVF stimulation has run almost entirely on injectable biologics for decades, and a credible oral FSHR/LHCGR agonist would be a genuine convenience disruption, expanding the addressable market to patients who avoid treatment due to injection burden. On price, "mid-double-digit millions" for two early/preclinical programs is a small, platform-validation-scale bet, not a transformative deal — size expectations accordingly. And for PostEra, getting bought for its output rather than its platform is a telling data point in the AI-drug-discovery debate: near-term value may sit in the assets, not the software.